Author: Ophthalmology

Author reply – Corrected Proof

by  •  • 0 Comments

We are pleased to receive comments regarding our manuscript reporting transsynaptic retrograde degeneration (TRD) of retinal ganglion cells after infarction in various areas of the brain. We measured retinal nerve fiber layer (RNFL) thickness to indire…

Read more →

Polymorphisms in Vascular Endothelial Growth Factor Receptor 2 Are Associated with Better Response Rates to Ranibizumab Treatment in Age-related Macular Degeneration – Corrected Proof

by  •  • 0 Comments

Purpose: Intravitreal anti–vascular endothelial growth factor (VEGF) injections are currently the standard treatment for neovascular age-related macular degeneration (AMD), but a broad range of response rates has been observed. We evaluated the assoc…

Read more →

Author reply – Corrected Proof

by  •  • 0 Comments

We thank Galvis et al for their letter. We also noted in our study that there are no differences in myopia progression when comparing myopic children with or without atropine treatment in both the intervention (recess outside classroom) and control gr…

Read more →

Clinical Pharmacokinetics of Intra-arterial Melphalan and Topotecan Combination in Patients with Retinoblastoma – Corrected Proof

by  •  • 0 Comments

Purpose: To assess the antitumor activity, toxicity, and plasma pharmacokinetics of the combination of melphalan and topotecan for superselective ophthalmic artery infusion (SSOAI) treatment of children with retinoblastoma.Design: Single-center, prospective, clinical pharmacokinetic study.Participants: Twenty-six patients (27 eyes) with intraocular retinoblastoma.Methods: Patients with an indication for SSOAI received melphalan (3–6 mg) and topotecan (0.5–1 mg; doses calculated by age and weight). Plasma samples were obtained for pharmacokinetic studies, and a population approach via nonlinear mixed effects modeling was used. Safety and efficacy were assessed and compared with historical cohorts of patients treated with melphalan single-agent SSOAI.Main Outcome Measures: Melphalan and topotecan (Read more...)

Intravitreal Anti–Vascular Endothelial Growth Factor for Submacular Hemorrhage from Choroidal Neovascularization – Corrected Proof

by  •  • 0 Comments

Purpose: To evaluate the efficacy of intravitreal anti–vascular endothelial growth factor (VEGF) monotherapy for patients diagnosed with exudative age-related macular degeneration (AMD) accompanied by submacular hemorrhage.Design: Retrospective, observational case series.Participants: Ninety-one eyes of 91 patients who initially presented with submacular hemorrhage associated with exudative AMD from October 2009 to September 2012. Patients were followed up for at least 6 months after treatment.Methods: Best-corrected visual acuity (BCVA) was measured at diagnosis and at 1, 3, and 6 months after treatment. The duration of symptoms was estimated. The extent of hemorrhage was estimated using fundus photography, and central foveal thickness was measured (Read more...)

Retinal Blood Vessel Positional Shifts and Glaucoma Progression – Corrected Proof

by  •  • 0 Comments

Purpose: To determine the characteristics and significance of retinal blood vessel (RBV) positional shifts over time in a cohort of patients with progressive glaucoma.Design: Retrospective cohort study.Participants: Baseline and serial stereophotographs from 1 eye of 125 patients with open-angle glaucoma with ≥8 reliable Swedish interactive threshold algorithm standard visual fields (VFs) were included. On the basis of global rates of threshold sensitivity change, patients with glaucoma were divided into groups of minimal (<−0.02 decibels [dB]/year), moderate (−0.02 to −0.65 dB/year), or fast (≥−0.65 dB/year) progression. To determine whether graders’ assessments of RBV positional shifts were false-positives, a control group consisting of (Read more...)

CABP4 Mutations Do Not Cause Congenital Stationary Night Blindness – Corrected Proof

by  •  • 0 Comments

I read with interest the analysis of Dutch patients diagnosed with congenital stationary night blindness (CSNB) by Bijveld et al, particularly what was written regarding patients with recessive mutations in calcium binding protein 4 (CABP4; Mendelian Inheritance in Man *608965). CABP4 encodes a protein that is specifically located in photoreceptor synaptic terminals, where it probably modulates photoreceptor calcium release. Only 3 of 101 patients diagnosed with CSNB in the authors’ series had CABP4 mutations, and all 3 patients (2 families) harbored the same homozygous mutation (c.646C>T; p.Arg216X). These 3 patients had nystagmus and low vision. Two were photophobic. All 3 had (Read more...)

Incidence of Visual Improvement in Uveitis Cases with Visual Impairment Caused by Macular Edema – Corrected Proof

by  •  • 0 Comments

Purpose: Among cases of visually significant uveitic macular edema (ME), to estimate the incidence of visual improvement and identify predictive factors.Design: Retrospective cohort study.Participants: Eyes with uveitis, seen at 5 academic ocular inflammation centers in the United States, for which ME was documented to be currently present and the principal cause of reduced visual acuity (<20/40).Methods: Data were obtained by standardized chart review.Main Outcome Measures: Decrease of ≥0.2 base 10 logarithm of visual acuity decimal fraction-equivalent; risk factors for such visual improvement.Results: We identified 1510 eyes (of 1077 patients) with visual impairment to a level <20/40 attributed to ME. Most (Read more...)